Stifel Maintains Buy on Neurocrine Biosciences, Raises Price Target to $215
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $188 to $215.
Stifel analyst Paul Matteis maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $188 to $215.